As an example, although addition of atezolizumab to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer did not significantly improve PFS in patients with PD-L1–positive tumors (≥1% immune cells), exploratory analyses demonstrated an improvement in PFS when a threshold of PD-L1 immune cells ≥5% was used in the IMagyn050/GOG 3015/ENGOT-OV39 trial.41 This evidence concerns the gene CD274 and ovarian carcinoma.